Christine Fox - 05 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: EVP, U.S. Commercial
Signature: /s/ Dov Bergwerk as attorney-in-fact for Christine Fox
Issuer symbol: TEVA
Transactions as of: 05 Mar 2026
Net transactions value: -$250,940
Form type: 4
Filing time: 09 Mar 2026, 16:16:34 UTC
Previous filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Fox Christine	EVP, U.S. Commercial	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Christine Fox	09 Mar 2026	0001998173

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+17,819	+24%		92,829	05 Mar 2026	Direct	F1, F2
transaction	TEVA	Ordinary Shares	Sale	$250,940	-7,924	-8.5%	$31.67	84,905	05 Mar 2026	Direct	F1, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise		-17,819	-25%	$0.000000^*	53,459	05 Mar 2026	Ordinary Shares	17,819		Direct	F1, F2, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
F4	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6	Restricted share units were granted on March 5, 2025, with 17,819 vested on March 5, 2026, 17,819 vesting on each of March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029.